(Q46207930)

20 December 2017

title

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus (English)

1 reference

20 December 2017

1 reference

Zhi-Xu He

1

1 reference

20 December 2017

Zhi-Wei Zhou

2

1 reference

20 December 2017

Yinxue Yang

3

1 reference

20 December 2017

Tianxin Yang

4

1 reference

20 December 2017

Si-Yuan Pan

5

1 reference

20 December 2017

Jia-Xuan Qiu

6

1 reference

20 December 2017

Shu-Feng Zhou

7

1 reference

20 December 2017

publication date

1 February 2015

1 reference

20 December 2017

Clinical and Experimental Pharmacology and Physiology

published in

1 reference

20 December 2017

volume

42

1 reference

20 December 2017

issue

2

1 reference

20 December 2017

page(s)

125-138

1 reference

20 December 2017

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive.

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Aldose reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

N-[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]- N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Dapagliflozin: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Linagliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Metformin pathways: pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Drug-induced hypoglycaemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Liraglutide: from clinical trials to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Amylin uncovered: a review on the polypeptide responsible for type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Adjunct therapy for type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pramlintide for the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pramlintide and the treatment of diabetes: a review of the data since its introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Antidiabetic agents: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Cellular and molecular mechanisms of metformin: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Bile acid sequestrants: more than simple resins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Role of bile acid sequestrants in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

21 January 2018

Incretin-based therapies

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Glucagon-like peptide 1 and appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

21 January 2018

Sitagliptin: a review

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Bromocriptine: old drug, new formulation and new indication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Modulation of monoaminergic neural circuits: potential for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

α-Glucosidase inhibitors and their use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as α-glucosidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Nateglinide: a new rapid-acting insulinotropic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Mitiglinide for type 2 diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

SGLT2 inhibitors for diabetes: turning symptoms into therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Canagliflozin: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

21 January 2018

Are sulfonylureas passé?

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Sulfonylurea stimulation of insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

KATP channels as molecular sensors of cellular metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

PPARdelta regulates glucose metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

21 January 2018

Thiazolidinedione safety

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Dual acting and pan-PPAR activators as potential anti-diabetic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Clinical pharmacokinetics and pharmacodynamics of linagliptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Ranirestat for the management of diabetic sensorimotor polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Sorbinil pharmacokinetics in male and female elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Pharmacokinetics of tolbutamide in ethnic Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Clinical pharmacokinetics of troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12332

21 January 2018

Identifiers

DOI

10.1111/1440-1681.12332

1 reference

20 December 2017

PubMed ID

25360831

1 reference

20 December 2017